Insulet (PODD)
(Delayed Data from NSDQ)
$184.28 USD
+7.88 (4.47%)
Updated May 7, 2024 04:00 PM ET
After-Market: $178.60 -5.68 (-3.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 161 - 180 ( 341 total )
Company: Insulet Corporation
Industry: Medical - Products
670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker: - Sequential Decline in August Reflects Historic Pattern After a Strong July; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Diabetes Technology Panel Highlights The Opportunities That Lie Ahead
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Kit Prescription Tracker Points to Significant Sequential Share Gain (However July Data May Be an Anomaly); Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Insulet Corporation
Industry: Medical - Products
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q2 well ahead, guidance raised, reiterate BUY, raising target to $39.25
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
2Q Results Highlighted by a Multitude of Positive Surprises; Increasing PT to $48 - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulet Corp. with OUTPERFORM: Onpro Kit exits 2Q with 40% share of Neulasta franchise and Continues to Grow
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulet Corp.with OUTPERFORM: Monthly Neulasta Onpro Kit Prescription Tracker Points To Further Share Gains; Setback To Novartis Biosimilar Positive For OPK; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices: 2Q16 MedTech Preview: Stable Trends and Healthy Underlying Fundamentals
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Diabetes: Artificial Pancreas Workshop Provides Insights On the Future of the Diabetes Market
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Kit Prescription Tracker Points Toward Further Share Gains in May; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
American Diabetes Association Meeting Suggests a Diabetes Technology Renaissance Is Coming; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Prescriptions Continue to Gain Share in April; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
International OmniPod Demand Expected to Remain Robust; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MDT/UHC Insulin Pump Agreement Could Become A Significant POSITIVE for the Other
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Volatility in Diabetes Stocks Following UNH/MDT Agreement Creates Buying Opportunity; Reiterate OUTPERFORM on DXCM, PODD, TNDM
Provider: WEDBUSH SECURITIES INC.